Piclidenoson

$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a single institutional investor of 8,333,333 of the Company’s American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 16,666,666 ADSs at a combined public offering price of $0.60 per ADS (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have an exercise price of $0.60 per ADS, are exercisable upon issuance and will expire twenty-four months following the date of issuance. The offering is expected to close on or about July 29, 2025, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering, before deducting the placement agent’s fees and other offering expenses payable by the Company, are expected to be approximately $5.0 million. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $10.0 million. No assurance can be given that any of such short-term warrants will be exercised. Can-Fite intends to use the net proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes. The securities described above are being offered and sold by Can-Fite pursuant to a registration statement on Form F-1 (File No. 333-288890), which was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on July 28, 2025. The offering is being made only by means of a prospectus forming a part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com. Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom and the exercise of the short-term warrants prior to their expiration. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@canfite.com +972-3-9241114 Released July 28, 2025

撰文丨王聪编辑丨王多鱼排版丨水成文本周（6 月 30-7 月 6 日），国际顶尖学术期刊 Cell 共上线了 5 篇研究论文，其中 4 篇来自华人学者，这些研究分别构建高度血管化的肺类器官和肠道类器官、发现血管性痴呆的大脑修复机制、开发LAG-3/TCR双抗，治疗T细胞驱动的自身免疫病、揭示同义突变通过表观转录组调控赋予黄瓜驯化性状。高度血管化的肺类器官和肠道类器官2025 年 6 月 30 日，辛辛那提儿童医院/加州大学洛杉矶分校顾名夏团队和辛辛那提儿童医院郭敏哲团队合作，在国际顶尖学术期刊 Cell 上发表了题为：Co-development of Mesoderm and Endoderm Enables Organotypic Vascularization in Lung and Gut Organoids 的研究论文。该研究首次通过人类诱导多能干细胞（iPSC）成功构建了高度血管化的肺类器官和肠道类器官。这些类器官模型不仅模拟了人类胚胎早期多胚层协同发育的复杂过程，更突破了传统类器官缺乏功能性血管和器官特异性间充质的瓶颈，为研究人类器官发育和疾病中的复杂细胞间通讯以及再生医学提供了一个先进的平台。论文第一作者兼共同通讯作者苗一非博士，现为中国科学院动物研究所人类器官生理病理模拟装置（HOPE）研究员；共同第一作者谈诚博士现为北京大学人民医院妇产科主治医师。发现血管性痴呆的大脑修复机制2025 年 6 月 30 日，加州大学洛杉矶分校 S. Thomas Carmichael 团队（博士后田敏为第一作者）在国际顶尖学术期刊 Cell 上发表了题为：Deconstructing the intercellular interactome in vascular dementia with focal ischemia for therapeutic applications 的研究论文。血管性痴呆（VaD）是仅次于阿尔茨海默病（AD）的痴呆症第二大病因，主要是一种白质缺血性疾病，目前尚无直接疗法，病变部位内的细胞间相互作用决定着疾病的进展或修复。该研究结合小鼠模型和人类数据，确定了血管性痴呆的大脑修复的关键信号通路——CD39-A3AR，并证明了一种处于 3 期临床试验阶段的治疗银屑病的 A3AR 特异性激动剂——Piclidenoson，能够促进大脑组织的修复，并恢复记忆和步态功能。有望为血管性痴呆这种研究不足的主要痴呆类型带来首个有效治疗方法。LAG-3/TCR双抗，治疗T细胞驱动的自身免疫病2025 年 6 月 30 日，纽约大学格罗斯曼医学院王俊教授团队联合中国科学院生物物理研究所娄继忠研究员团队、浙江大学医学院陈伟教授团队（Jasper Du、陈辉、由佳为共同第一作者），在国际顶尖学术期刊 Cell 发表了题为：Proximity between LAG-3 and the T Cell Receptor Guides Suppression of T Cell Activation and Autoimmunity 的研究论文。该研究首次系统性揭示了 LAG-3 抑制受体由其经典配体 MHC-II 调控的条件性激活机制：LAG-3 并非简单依赖配体结合本身，而是依赖 MHC-II 介导的 TCR 空间邻近效应，使 LAG-3 与 TCR 复合物形成顺式共定位，从而实现对 CD4+ T 细胞的有效抑制。这一发现颠覆了人们对免疫检查点（特别是LAG-3）激活机制的传统认知。LAG-3 对激活条件的高度依赖性，意味着其在体内难以被有效触发；但这也为精准干预自身免疫性 T 细胞提供了独特机会。基于这一机制，王俊团队创新性地开发了靶向 LAG-3 与 TCR 的双特异 T 细胞抑制抗体（Bispecific T cell silencer，BiTS），可特异性调控 LAG-3 阳性的致病性 T 细胞，并在多种自身免疫疾病动物模型中展现出显著的治疗效果。同义突变通过表观转录组调控赋予黄瓜驯化性状2025 年 7 月 1 日，中国农业科学院蔬菜花卉研究所杨学勇研究员、中国农业科学院（深圳）农业基因组研究所黄三文院士、英国约翰英纳斯研究中心丁一倞研究员作为共同通讯作者（中国农业科学院蔬菜花卉研究所辛同旭博士、河南大学张震副教授、英国约翰英纳斯中心张月莹博士和中国农业科学院蔬菜花卉研究所已毕业硕士生李旭彤为共同第一作者），在国际顶尖学术期刊 Cell 上发表了题为：Recessive epistasis of a synonymous mutation confers cucumber domestication through epitranscriptomic regulation 的研究论文。该研究首次在遗传学上证明了同义突变可通过改变 m6A 修饰和 mRNA 结构构象来调控驯化的重要性状。这一发现挑战了传统认知，同时凸显出同义突变在作物改良策略中可能具有重要价值。未来深入研究同义突变在 RNA 修饰与结构调控中的功能，有望为作物改良开辟新的路径。论文链接：1. https://www.cell.com/cell/abstract/S0092-8674(25)00628-22. https://www.cell.com/cell/fulltext/S0092-8674(25)00636-13. https://www.cell.com/cell/abstract/S0092-8674(25)00638-54. https://www.cell.com/cell/fulltext/S0092-8674(25)00674-9设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群 微信加群 为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味